Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some cases, patients with stage IIIA-N2 NSCLC are considere...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	ESMO open 2022-04, Vol.7 (2), p.100410-100410, Article 100410
Hauptverfasser:	Senan, S., Özgüroğlu, M., Daniel, D., Villegas, A., Vicente, D., Murakami, S., Hui, R., Faivre-Finn, C., Paz-Ares, L., Wu, Y.L., Mann, H., Dennis, P.A., Antonia, S.J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Chemoradiotherapy chemotherapy Disease Progression Humans immunotherapy Lung Neoplasms - drug therapy multimodality therapy Original Research radiation therapy surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!